

Clostridioides difficile (C. diff) Infection PREVENTION AND TREATMENT

For Clinicians and Health Care Professionals

What are the steps to prevent the spread of C. diff?

If a resident has more than three stools in 24 hours:

- · Immediately initiate contact precautions and separate residents, even if a C. diff infection is only suspected.
- · Even for brief visits, always use gloves and a gown when attending to residents with suspected C. diff infections.
- Request a C. diff test when other potential causes of diarrhea, such as stool softeners or laxatives, are unlikely.
- · Discontinue laxatives and wait for at least 48 hours before testing if the resident is still symptomatic.
- When evaluating a resident for C. diff, consider whether the antibiotics used to treat the resident are appropriate.

If the resident is positive for C. diff:

- · Continue standard and contact precautions.
- · Perform hand washing with soap and water.
- · Use antibiotics appropriately.
- Ensure daily comprehensive cleaning of room surfaces with an EPA-approved sporicidal disinfectant when treating a resident with C. diff and when the resident is discharged or transferred.
- · When the resident transfers, notify the new facility if the resident has or had a C. diff infection.



What are the treatment options for C. difficile infections?



For initial C. diff infection episode (IDSA and SHEA 2021):

- Preferred: Fidaxomicin 200 mg given twice daily for 10 days
- · Alternative: Vancomycin 125 mg given four times daily by mouth for 10 days
- Alternative for non-severe C. diff infection, if above agents are unavailable:
 Metronidazole, 500 mg three times daily by mouth for 10–14 days

For the first C. diff infection recurrence (IDSA and SHEA 2021):

- Preferred: Fidaxomicin 200 mg given twice daily for 10 days, OR twice daily for five days followed by once every other day for 20 days
- · Alternative: Vancomycin by mouth in a tapered and pulsed regimen
- · Alternative: Vancomycin 125 mg given four times daily by mouth for 10 days
- Adjunctive treatment: Bezlotoxumab 10 mg/kg given intravenously once during administration of standardof-care antibiotics
- * For second, subsequent, and fulminant C. diff infections, it is recommended to refer to an Infectious Disease physician.

Resource: The Centers for Disease Control and Prevention

This material was prepared by Alliant Health Solutions, a Quality Innovation Network – Quality Improvement Organization (QIN – QIO) under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this material do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. Publication No. 12SOW-AHS-QIN-QIO-TOI-NH-TOI-PCH-5171-01/29/24

